The relation between soluble apoptotic proteins and subclinical cardiotoxicity in adjuvant-treated breast cancer patients.

BACKGROUND Circulating apoptotic proteins are increased in heart failure patients. We evaluated whether circulating soluble apoptosis-related protein levels change after anthracycline-containing chemotherapy and radiotherapy in relation to cardiac dysfunction or the applied treatment. PATIENTS AND METHODS Circulating apoptotic proteins were measured with immunoassay in 40 breast cancer patients following surgery (TO), one month (T1) and one year (T2) after epirubicin-based chemotherapy. Standard-dose (n=21) or high-dose (n=19) myeloablative chemotherapy, preceded irradiation and tamoxifen. Circulating apoptotic proteins were compared with previous cardiac evaluations. RESULTS Soluble tumor necrosis factor receptor 1 (+30%), 2 (+43%) and Fas (+40%) were transiently increased at T1 compared to T0, whereas Fas ligand (-64%) was transiently decreased, especially in the high-dose group. Apoptosis markers were not associated with cardiac dysfunction. CONCLUSION Significant, but transient changes in soluble apoptotic protein levels were observed, particularly after high-dose chemotherapy. No relation was found between apoptosis-related proteins and cardiotoxicity.

[1]  P. Morandi,et al.  Cardiac toxicity of high-dose chemotherapy , 2005, Bone Marrow Transplantation.

[2]  E. D. de Vries,et al.  The dilemma of the strive for apoptosis in oncology: mind the heart. , 2005, Critical reviews in oncology/hematology.

[3]  E. D. de Vries,et al.  ENDOTOXIN INCREASES PLASMA SOLUBLE TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND LEVEL MEDIATED BY THE p38 MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING PATHWAY , 2004, Shock.

[4]  E. D. de Vries,et al.  Circulating apoptosis-related proteins in long-term disease free breast cancer survivors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Yin,et al.  Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. , 2004, American heart journal.

[6]  E. D. de Vries,et al.  Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage. , 2004, European journal of cancer.

[7]  S. Sheen-Chen,et al.  Serum concentration of tumor necrosis factor in patients with breast cancer , 1997, Breast Cancer Research and Treatment.

[8]  B. Jilma,et al.  Regulation of Fas (APO-1, CD95) and Fas Ligand Expression in Leukocytes During Systemic Inflammation in Humans , 2003, Shock.

[9]  G. Schuler,et al.  Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. , 2003, Journal of the American College of Cardiology.

[10]  S. Rodenhuis,et al.  High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. , 2003, The New England journal of medicine.

[11]  S. Sheen-Chen,et al.  Circulating Soluble Fas in Patients with Breast Cancer , 2003, World Journal of Surgery.

[12]  S. Frøland,et al.  Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. , 2002, Cardiovascular research.

[13]  M. Kinoshita,et al.  Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[14]  M. P. van den Berg,et al.  Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Maseri,et al.  Enhanced Response of Blood Monocytes to In Vitro Lipopolysaccharide-Challenge in Patients With Recurrent Unstable Angina , 2001, Circulation.

[16]  D. Sleijfer,et al.  Adsorptive Voltametry to Determine Platinum Levels in Plasma From Testicular Cancer Patients Treated With Cisplatin , 2001, Therapeutic drug monitoring.

[17]  D. Sleijfer,et al.  Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer , 2000, The Lancet.

[18]  M. Toi,et al.  Circulating soluble Fas concentration in breast cancer patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  E. Jabłońska.  Changes in sIL-6R and sTNF-Rs release by PMNs and the serum levels in breast cancer patients at different stages of treatment. , 1998, Cytokine.

[20]  S. Nomura,et al.  Changes of immunological markers after autologous peripheral blood stem cell transplantation , 1998, Journal of Cancer Research and Clinical Oncology.

[21]  M. Takemura,et al.  Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. , 1997, Journal of the American College of Cardiology.

[22]  A. Nagler,et al.  Soluble tumor necrosis factor (sTNF) receptors: a possible prognostic marker for bone marrow transplantation-related complications. , 1996, Cytokines and molecular therapy.

[23]  R. Virmani,et al.  Apoptosis in myocytes in end-stage heart failure. , 1996, The New England journal of medicine.

[24]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[25]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[26]  D. Mann,et al.  Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. , 1996, Circulation.

[27]  M. Miura,et al.  Tumor necrosis factor-induced apoptosis is mediated by a CrmA-sensitive cell death pathway. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Fiucci,et al.  Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. , 1995, Journal of immunology.

[29]  Masato Tanaka,et al.  Expression of the functional soluble form of human fas ligand in activated lymphocytes. , 1995, The EMBO journal.

[30]  L. Moldawer,et al.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[32]  S. Colan,et al.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.

[33]  W. Lehmacher,et al.  Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. , 1990, Blood.

[34]  W. Lehmacher,et al.  Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. , 1990, Blood.

[35]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[36]  D. V. Von Hoff,et al.  Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. , 1977, The American journal of medicine.